APA (7th ed.) Citation

Sandercock, P., Wardlaw, J., Lindley, R., Dennis, M., Cohen, G., Murray, G., . . . Arauz, A. (2012). The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial.

Chicago Style (17th ed.) Citation

Sandercock, P., et al. The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator Within 6 H of Acute Ischaemic Stroke (the Third International Stroke Trial [IST-3]): A Randomised Controlled Trial. 2012.

MLA (9th ed.) Citation

Sandercock, P., et al. The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator Within 6 H of Acute Ischaemic Stroke (the Third International Stroke Trial [IST-3]): A Randomised Controlled Trial. 2012.